SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer

PURPOSE: Cixutumumab, formerly IMC-A12, is a recombinant human monoclonal immunoglobulin G(1) antibody that targets insulin-like growth factor I receptor (IGF-IR). Cixutumumab was synergistic with castration in a hormone-sensitive prostate cancer xenograft model. PATIENTS AND METHODS: Patients with...

全面介紹

Na minha lista:
書目詳細資料
發表在:J Clin Oncol
Main Authors: Yu, Evan Y., Li, Hongli, Higano, Celestia S., Agarwal, Neeraj, Pal, Sumanta K., Alva, Ajjai, Heath, Elisabeth I., Lam, Elaine T., Gupta, Shilpa, Lilly, Michael B., Inoue, Yoshio, Chi, Kim N., Vogelzang, Nicholas J., Quinn, David I., Cheng, Heather H., Plymate, Stephen R., Hussain, Maha, Tangen, Catherine M., Thompson, Ian M.
格式: Artigo
語言:Inglês
出版: American Society of Clinical Oncology 2015
主題:
ORIGINAL REPORTS
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4417730/
https://ncbi.nlm.nih.gov/pubmed/25847934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.59.4127
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍